I-Mab (NASDAQ:IMAB - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect I-Mab to post earnings of ($0.12) per share for the quarter.
I-Mab Trading Down 1.1 %
I-Mab stock traded down $0.01 during midday trading on Friday, reaching $0.86. The stock had a trading volume of 128,760 shares, compared to its average volume of 316,172. I-Mab has a twelve month low of $0.76 and a twelve month high of $2.00. The firm's fifty day simple moving average is $0.98 and its two-hundred day simple moving average is $1.07.
Analyst Ratings Changes
A number of research firms have issued reports on IMAB. Brookline Capital Management upgraded shares of I-Mab to a "strong-buy" rating in a research report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of I-Mab in a research report on Friday, November 15th.
Get Our Latest Research Report on IMAB
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Further Reading
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
